Characteristics of patients who would benefit from implanted cardioverter-defibrillator treatment*
| *Derived from trial data and clinical evidence.10,21–26 | |
| EPS, electrophysiological study; LVEF, left ventricular ejection fraction; MI, myocardial infarction; VT, ventricular tachycardia. | |
| Primary prevention | Patients surviving cardiac arrest |
| Patients having symptomatic sustained ventricular tachyarrhythmias | |
| Patients with symptomatic sustained ventricular tachyarrythmias and LVEF ≤40% | |
| Secondary prevention | Patients having underlying coronary heart disease with unsustained VT and inducible VT on EPS |
| Patients post MI with unsustained VT, LVEF ≤35% with inducible VT not suppressed by procaineamide with no indications for coronary artery surgery within 3 months | |
| Other | Long QT syndrome |
| Brugada syndrome | |
| Hypertropic obstructive cardiomyopathy | |